Distinguishing between Individual Direct Oral Anticoagulants on the Basis of their Specific Characteristics
Mami Sakurai, Yuya Ise, Shirou Katayama
Abstract
Open-access reader
Mami Sakurai, Yuya Ise, Shirou Katayama
Abstract
Open-access reader
Before dabigatran was introduced in 2011, vitamin K antagonist was for nearly 50 years the only oral anticoagulant available. Including dabigatran, there are now four non-vitamin K antagonist direct oral anticoagulants (DOACs), which has greatly increased treatment options. However, the increased number of options has led to some confusion in the selection of appropriate anticoagulants in specific cases. In this paper, we outline the characteristics of each individual DOAC on the basis of recent reports.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Before dabigatran was introduced in 2011, vitamin K antagonist was for nearly 50 years the only oral anticoagulant available. Including dabigatran, there are now four non-vitamin K antagonist direct oral anticoagulants (DOACs), which has greatly increased treatment options. However, the increased number of options has led to some confusion in the selection of appropriate anticoagulants in specific cases. In this paper, we outline the characteristics of each individual DOAC on the basis of recent reports.
Key concepts: Dabigatran, Vitamin K antagonist, Confusion, Medicine, Rivaroxaban, Oral anticoagulant, Vitamin k, Intensive care medicine